Table 1.
Clinical severity score (CSS) changes following 6-month ω-3 PUFAs supplementation in stage I RTT patients (individual items)
| Clinical manifestation | Severity Score | P value | |
|---|---|---|---|
| Before ω-3 PUFAs supplementation | After ω-3 PUFAs supplementation (6 months) |
||
| Age of onset of regression | 4 [4–4] | 4 [4–4] | 1.0 |
| Somatic growth | 1.5 [1–2] | 1 [1–2] | 0.8182 |
| Head growth | 3 [3–3] | 3 [3–3] | 1.0 |
| Motor/independent sitting | 4 [4–4] | 0 [0–1] | 0.0087 |
| Ambulation | 5 [5–5] | 1 [1–4] | 0.0152 |
| Hand use | 4 [4–4] | 2 [2–2] | 0.0022 |
| Scoliosis | 0 [0–0] | 0 [0–0] | 1.0 |
| Language | 4 [4–4] | 3 [3–4] | 0.0649 |
| Nonverbal communication | 5 [5–5] | 0 [0–1] | 0.0022 |
| Respiratory dysfunction | 4 [4–4] | 1 [0–1] | <0.0001 |
| Autonomic symptoms | 0 [0–0] | 0 [0–0] | 1.0 |
| Onset of stereotypies | 4 [4–4] | 4 [4–4] | 1.0 |
| Epilepsy/seizures | 0 [0–0] | 0 [0–0] | 1.0 |
The values are medians and inter-quartile ranges. CSS was assessed according to Neul et al. 2008. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome